CLINICAL TRIALS PROFILE FOR VECTICAL
✉ Email this page to a colleague
All Clinical Trials for VECTICAL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00419666 ↗ | A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis | Completed | Galderma | Phase 2 | 2006-08-01 | This is an open-label, multicenter study to assess the systemic exposure to calcitriol in the adolescent population. Calcitriol 3µg/g ointment (2 mg/cm² per application) is to be applied twice daily to involved skin (10 - 35% BSA involved, excluding face, scalp and intertriginous areas) for 56 days (8 weeks). Full Pharmacokinetic (PK) and Pharmacodynamic (PD) profile will be collected during the first 3 weeks of the study; safety and efficacy data will be collected for the 8 weeks of the treatment. |
| NCT00419666 ↗ | A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis | Completed | Galderma R&D | Phase 2 | 2006-08-01 | This is an open-label, multicenter study to assess the systemic exposure to calcitriol in the adolescent population. Calcitriol 3µg/g ointment (2 mg/cm² per application) is to be applied twice daily to involved skin (10 - 35% BSA involved, excluding face, scalp and intertriginous areas) for 56 days (8 weeks). Full Pharmacokinetic (PK) and Pharmacodynamic (PD) profile will be collected during the first 3 weeks of the study; safety and efficacy data will be collected for the 8 weeks of the treatment. |
| NCT00988637 ↗ | Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis | Completed | Galderma Laboratories, L.P. | Phase 4 | 2009-10-01 | This clinical trial will evaluate the efficacy and safety of Clobex® (clobetasol propionate) Spray 0.05% and Vectical™ (calcitriol) Ointment 3 µg/g over a four week period of use in one of two different regimens: 1. Vectical™ Ointment treatment, twice daily on weekdays (Mon - Fri) and Clobex® Spray treatment twice daily on weekends (Sat - Sun) for 28 days 2. Clobex® Spray once each morning and Vectical™ Ointment once each evening for 28 days |
| NCT01012713 ↗ | Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis | Completed | University of California, San Francisco | Phase 4 | 2010-06-01 |
This is a 12-week, open-label, pilot trial evaluating the efficacy and safety of the
combination of Clobex® spray with excimer laser therapy as the initial treatment of
generalized plaque psoriasis, followed by maintenance therapy with topical Vectical. The
study will be conducted in three distinct periods, namely Period A, Period B, and Period C,
each of 4 weeks duration. During Period A (weeks 1 through 4), patients will use Clobex®
spray twice daily along with excimer laser treatments twice weekly with the Photomedex XTRAC®
Velocity machine. The goal of Period A is to achieve Psoriasis Area Severity Index (PASI) 75
in 100% of patients within four weeks. During Period B (weeks 5 through 8), patients would be
treated with topical Vectical® twice daily. Thus, there is a steroid-free interval during
which patients will not be using Clobex® spray. The goal of Period B is to maintain the
patient's response using only non-steroid options. During Period C of the study, patients
will use Clobex® spray BID and Vectical® BID. Period C (weeks 9 through 12) will be a
"booster" period in which the goal is to see if 100% of patients can achieve Psoriasis Area
Severity Index (PASI) 90-100. Regarding excimer laser therapy: all patients will be receiving
excimer laser therapy twice weekly for the first 6 weeks of the study (up to the halfway
point) which is 12 excimer laser treatments. At that point, only those patients achieving
|
| NCT01205880 ↗ | Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis | Completed | Galderma Laboratories | Phase 4 | 2009-12-01 | This investigator-blinded study is designed to assess whether the order of application affects the efficacy of the combination treatment Clobex® Spray (clobetasol propionate) and Vecitcal® (calcitriol) Ointment in plaque psoriasis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VECTICAL
Condition Name
Clinical Trial Locations for VECTICAL
Trials by Country
Clinical Trial Progress for VECTICAL
Clinical Trial Phase
Clinical Trial Sponsors for VECTICAL
Sponsor Name
